Supernus Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Supernus Pharmaceuticals Stock Forecast and Price Target
The average target price for Supernus Pharmaceuticals's stock set by renowned analysts in recent months is $40.50, representing a potential upside of approximately 24.88% from its last closing price if met by 2025. This estimation is based on a high estimate of $43.00 and a low estimate of $38.00. If you are interested in SUPN stock, you should also look at its competitors.
24.88% Upside
Supernus Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Supernus Pharmaceuticals has seen a decline in its Price, from $39.39 to $0.00 – a 100.00% decrease. In the next year, analysts believe that Fair Value will reach $32.38 – an increase of 100.00%. For the next seven years, the forecast is forFair Value to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
5
|
¥4.31k | Buy/Sell | ¥4.74k | 6.63% |
TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$13.35 | Buy/Sell | $11.59 | 19.85% |
4151 Stock Forecast | Kyowa Kirin | Outperform |
18
|
¥2.86k | Buy/Sell | ¥3.06k | 4.82% |
JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$116.63 | Buy/Sell | $188.32 | 59.52% |
Supernus Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Supernus Pharmaceuticals's Revenue has seen growth In the last three years, going from $520.40M to $607.52M – a gain of 16.74% In the next year, analysts believe that Revenue will reach $624.59M – an increase of 2.81%. For the next seven years, the forecast is forRevenue to grow by 43.21%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£19.10 | Buy/Sell | £28.11 | 55.34% |
ALKS Stock Forecast | Alkermes | Outperform |
10
|
$28.60 | Buy/Sell | $33.27 | 18.88% |
PBH Stock Forecast | Prestige Consumer Healthcare | Outperform |
16
|
$74.58 | Buy/Sell | $71.50 | -0.11% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$9.12 | Buy/Sell | $9.50 | -1.32% |
AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$43.81 | Buy/Sell | $69.00 | 41.52% |
IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.95 | Buy/Sell | $17.83 | 95.53% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$5.38 | Buy/Sell | $6.13 | 23.23% |
PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$31.02 | Buy/Sell | $47.90 | 45.07% |
ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$66.13 | Buy/Sell | $69.75 | 20.22% |
Supernus Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
Supernus Pharmaceuticals's EBITDA has decreased In the last three years, from $202.14M to $98.26M – a 51.39% drop. In the following year, 2 experts forecast Supernus Pharmaceuticals's EBITDA will decrease by 2.52%, to $95.78M. The Supernus Pharmaceuticals forecast is for EBITDA to reach $201.26M or grow by 104.82%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
COPN Stock Forecast | Cosmo Pharmaceuticals N.V. | Buy |
12
|
CHF67.50 | Buy/Sell | CHF76.55 | 25.82% |
COLL Stock Forecast | Collegium Pharmaceutical | Outperform |
11
|
$37.50 | Buy/Sell | $37.75 | 6.67% |
BDSI Stock Forecast | BioDelivery Sciences Internati... | - |
11
|
$5.59 | Buy/Sell | $10.00 | 16.46% |
Supernus Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Supernus Pharmaceuticals's EBIT has seen a drop from $184.00M to $13.40M – a 92.72% decrease. For next year, the 3 analysts predict EBIT of $116.62M, which would mean an increase of 770.30%. Over the next seven years, the pros' prediction is EBITof $406.50M, which would mean a seven-year growth forecast of 2933.58%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AQST Stock Forecast | Aquestive Therapeutics | Buy |
0
|
$4.94 | Buy/Sell | $6.33 | 61.94% |
CHRS Stock Forecast | Coherus BioSciences | Outperform |
6
|
$2.27 | Buy/Sell | $10.86 | 274.45% |
ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$0.93 | Buy/Sell | $3.50 | 276.34% |
Supernus Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Supernus Pharmaceuticals has seen a decline in its EPS, from $2.36 to $0.00 – a 100.00% decrease. In the next year, analysts believe that EPS will reach $1.94 – an increase of 100.00%. For the next seven years, the forecast is forEPS to grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
EGRX Stock Forecast | Eagle Pharmaceuticals | - |
14
|
$5.87 | Buy/Sell | $17.00 | -100.00% |
DRRX Stock Forecast | DURECT | Outperform |
9
|
$1.01 | Buy/Sell | $6.75 | 568.32% |
CPIX Stock Forecast | Cumberland Pharmaceuticals | - |
0
|
$2.03 | Buy/Sell | $8.50 | -100.00% |